Fenofibrate Inhibitor CAS No. 49562-28-9

Cat. No.	Name	Size	Price	Add Cart
KI0751	Fenofibrate	50 mg	$154

Chemical Characteristic

Product Name	Fenofibrate
Synonyms	Lipofen, Trilipix, Tricor, Lofibra, Lipidil, Supralip, Fenogal
CAS No.	49562-28-9
Molecular Weight	360.83
Formula	C₂₀H₂₁ClO₄
Chemical Structure

Biological activities

Fenofibrate is a peroxisome proliferator activated receptorα(PPARα) activator. Fenofibrate is useful in prevention and treatment of myocardial disease associated with hypertension and hyperlipidemia.^[1] Fenofibrate has a great affinity at PPARα receptor with an EC50 of 10 µM. ^[2] Fenofibrate inhibits proliferation and induces apoptosis in Ishikawa endometrial cancer cells. ^[3] Fenofibrate suppresses endothelial cell proliferation and VEGF production, increases TSP-1 and endostatin, and inhibits corneal neovascularization. ^[4] Fenofibrate lowers serum triglycerides and decreases body weight gain in fatty Zucker rats. ^[1]In ob/ob mice, fenofibrate prevents the rosiglitazone-induced weight gain. ^[2] Furthermore, fenofibrate treatment decreases total cholesterol and esterified cholesterol contents and reduces monocyte chemoattractant protein-1 (MCP-1) mRNA levels in the descending aortas of apoE-deficient mice. In apoE-deficient mice expressing a human apoA-I transgene, fenofibrate increases human apoA-I plasma and hepatic mRNA levels without affecting plasma lipid levels. ^[5] Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. ^[6] Fenofibrate prevents development of hypertension, and improves myocardial inflammation and collagen deposition in Ang II-infused rats. ^[7]

Protocols

Fenofibrate is dissolved in DMSO solution to a maximum of 1% v/v DMSO. ^[3]

References

[1] Chaput E, et al. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000, 271(2): 445-450. 閵嗏偓閵嗏偓 [2] Mittra S, et al. Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol. 2007, 150(4): 480-487. 閵嗏偓閵嗏偓 [3] Saidi SA, et al. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006, 5: 13. 閵嗏偓閵嗏偓 [4] Panigrahy D, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A. 2008, 105(3): 985-990. 閵嗏偓閵嗏偓 [5] Duez H, et al. Reduction of atherosclerosis by the peroxisome proliferator -activated receptor alpha agonist fenofibrate in mice. J Biol Chem. 2002, 277(50): 48051-48057. 閵嗏偓閵嗏偓 [6] Gu鑼卹in M, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996, 16(6): 763-772. 閵嗏偓閵嗏偓 [7] Diep QN, et al. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol. 2004, 36(2): 295-304. 閵嗏偓閵嗏偓

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.